NGS is now embedded in diagnostic frameworks, including the WHO 2022 and ICC classifications, which incorporate recurrently mutated genes such as TP53, ASXL1, RUNX1, and FLT3. This evidence concerns the gene TP53 and intrahepatic cholangiocarcinoma.